Carlos Monteiro (CEO of Biojam Holding Group) answered some questions related to the NEW COVID-19 Saliva tests.
Listen to the full interview here.
Some of the questions that are answered in this interview.
- What does the rapid saliva test consist of?
- What is the difference and advantage compared to conventional antigen tests?
- In terms of performance, do the tests meet the criteria defined by the DGS (sensitivity greater than or equal to 90% and specificity greater than or equal to 97%)?
- Have the tests already been authorized by Infarmed?
- Have usage guidelines been defined or are the same ones for antigen tests applicable?
- Could these new saliva tests replace conventional antigen tests that are being used on a large scale through the CVP?
- Are the tests already being marketed? If yes, where can they be purchased?
- Where can the test be taken?
- Can the saliva test also be prescribed and reimbursed by the SNS?
- Being a non-invasive saliva test, can it be purchased and performed by anyone?
- Where are the tests produced?
- Are there more companies selling this test in Portugal?
- Does Biojam have operational capacity for the acquisition and distribution of tests on a large scale in Portugal?
- What is the price of the test?
